Nettet6. jul. 2024 · The largest stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) was held by ARK Investment Management, which reported holding $771.4 million worth of stock at … Nettet21. nov. 2024 · Intellia Therapeutics is currently trading at 129.48 $ per share (November 19th) with a market cap of 9.64 bn$. The stock has been showing a strong price increase throughout the year, with ...
Intellia Therapeutics Sinks as Patent Ruling Overshadows Crispr …
Nettet31. aug. 2024 · Intellia's share price leapt from $80, to $172 - a gain of ~115% - in late June this year after the company released landmark datafrom a Phase 1 trial of its lead candidate NTLA-2001, in patients... Nettet1. des. 2024 · Intellia, however, has risen 114.96% this year. Wood is also bullish on Teladoc , which is the top holding in the ARK Genomic Revolution ETF and heavily weighted in other ARK funds as well. film dead man down
Is Intellia a Good Gene-Editing Stock to Buy Now?
Nettet23. des. 2024 · Intellia currently trades at a $4 billion market cap and remains very well funded. The opportunity here is obvious, a complete transformation of the way the world treats and cures diseases, and... Nettet10. jul. 2024 · Healthcare is undergoing a genomics revolution, and Intellia Therapeutics (NASDAQ: NTLA) is leading the way. Founded by Jennifer Doudna, who won the 2024 Nobel Prize in Chemistry for her... NettetAll medical breakthroughs have to start somewhere, and Intellia Therapeutics is ready to show the world the first-in-human gene editing data that could be the start of a film dead men walk